查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1671096

全球血友病 A 治疗市场：市场规模、占有率、趋势、行业分析（依治疗类型、治疗方法、通路和地区）、未来预测（2025-2034年）

Hemophilia A Treatment Market Size, Share, Trends, Industry Analysis Report: By Treatment Type, Therapy Type, Distribution Channel, and Region - Market Forecast, 2025-2034
出版日期: | 出版商: Polaris Market Research | 英文 116 Pages | 商品交期: 最快1-2个工作天内

价格

根据 Polaris Market Research 的一项新研究，全球血友病 A 治疗市场预计到2034年将达到 198.6亿美元。本研究报告对当前市场动态提供了详细的见解，并对未来市场成长进行了分析。

血友病 A 治疗是指透过医疗介入来管理和治疗血友病 A。这种遗传性疾病会导致血液凝结因子 VIII 不足，导致血液难以凝结并增加过度出血的风险。血友病 A 的主要治疗方法是透过重组或血浆衍生的凝血因子替代疗法来补充缺失的凝血因子。

血友病 A 治疗市场受到基因疗法、延长半衰期的因子 VIII 药物以及非因子替代疗法（如 emicizumab）等治疗方案的进步所推动。人们对血友病及其管理的认识不断提高以及医疗保健投资不断增加，改善治疗的机会，尤其是在新兴市场。

存在开发创新疗法的机会，这些疗法可以解决遗传根本原因，并透过皮下注射等侵入性较小的治疗方法提高患者的依从性。一个显着的趋势是开发延长半衰期的VIII 因子製剂，可以减少给药频率。此外，对非因子替代产品和基因编辑技术等创新治疗方法的大量投资塑造市场格局。

血友病 A 治疗市场：概论

根据治疗类型，预防性治疗（可预防出血发作并改善患者的生活品质）占血友病 A 治疗市场的最大占有率。它日益被提倡为长期治疗选择，尤其是对于年轻患者。

根据治疗类型，第VIII 因子製剂广泛用于按需治疗和预防，其中重组疗法和血浆衍生的第VIII 因子产品占据市场主导地位。基因治疗和单株抗体是成长最快的领域，并可能提供长期解决方案。

医院药局在急性和紧急护理中发挥关键作用，是主要的通路。专业药房经历最快的成长，特别是在基因疗法和单株抗体等先进疗法领域。

北美占据最大的市场占有率，这得益于完善的医疗保健基础设施和创新疗法的高采用率。由于医疗保健覆盖面的扩大、患者意识的增强以及对新兴经济体的投资不断增加，亚太地区经历快速成长。

目录

第1章 简介

第2章 执行摘要

第3章 分析方法

第4章 血友病 A 治疗市场洞察

  • 市场概况
  • 血友病 A 治疗的市场动态
    • 驱动因素和机会
      • 基因治疗的进展
      • 采用半衰期延长产品
      • 非因子替代疗法的兴起
    • 阻碍因素和挑战
      • 医疗费用上涨
  • PESTLE 分析
  • 血友病 A 治疗市场趋势
  • 价值链分析
  • COVID-19 影响分析

第5章 全球血友病 A 治疗市场（依治疗类型）

  • 主要调查结果
  • 简介
  • 按需
  • 治疗
  • 预防

第6章 全球血友病 A 治疗市场（依治疗类型）

  • 主要调查结果
  • 简介
  • 因子替代疗法
  • 去氨加压素纤维蛋白密封剂
  • 基因治疗/单株抗体

第7章 全球血友病 A 治疗市场（依通路）

  • 主要调查结果
  • 简介
  • 医院药房
  • 专业药房

第8章 全球血友病 A 治疗市场（依地区）

  • 主要调查结果
  • 简介
    • 依地区对血友病 A 治疗市场的评估（2020年至2034年）
  • 北美洲
    • 北美：依治疗类型（2020-2034年）
    • 北美：依治疗类型（2020-2034年）
    • 北美：依通路（2020-2034年）
    • 美国
    • 加拿大
  • 欧洲
    • 欧洲：依治疗类型（2020-2034年）
    • 欧洲：依治疗类型（2020-2034年）
    • 欧洲：依通路（2020-2034年）
    • 英国
    • 法国
    • 德国
    • 义大利
    • 西班牙
    • 荷兰
    • 俄罗斯
    • 其他欧洲国家
  • 亚太地区
    • 亚太地区：依治疗类型（2020-2034年）
    • 亚太地区：依治疗类型（2020-2034年）
    • 亚太地区：依通路（2020-2034年）
    • 中国
    • 印度
    • 马来西亚
    • 日本
    • 印尼
    • 韩国
    • 澳洲
    • 其他亚太地区
  • 中东和非洲
    • 中东和非洲：依治疗类型（2020-2034年）
    • 中东和非洲：依治疗类型（2020-2034年）
    • 中东和非洲：依通路（2020-2034年）
    • 沙乌地阿拉伯
    • 阿拉伯联合大公国
    • 以色列
    • 南非
    • 其他中东和非洲地区
  • 拉丁美洲
    • 拉丁美洲：依治疗类型（2020-2034年）
    • 拉丁美洲：依治疗类型（2020-2034年）
    • 拉丁美洲：依通路（2020-2034年）
    • 墨西哥
    • 巴西
    • 阿根廷
    • 其他拉丁美洲国家

第9章 竞争格局

  • 扩张与收购分析
    • 扩张
    • 收购
  • 伙伴关係/协作/协议/公开

第10章 公司简介

  • CSL Behring
  • Pfizer Inc.
  • Novo Nordisk A/S
  • Takeda Pharmaceutical Company Limited
  • Bayer AG
  • Sanofi（through its acquisition of Bioverativ）
  • F. Hoffmann-La Roche Ltd.
  • Octapharma AG
  • Grifols S.A.
  • BioMarin Pharmaceutical Inc.
  • Spark Therapeutics（a subsidiary of Roche）
  • Aptevo Therapeutics
  • Kedrion Biopharma
  • Sangamo Therapeutics
  • uniQure N.V.
Product Code: PM1107

The global hemophilia A treatment market size is expected to reach USD 19.86 billion by 2034, according to a new study by Polaris Market Research. The report "Hemophilia A Treatment Market Size, Share, Trends, Industry Analysis Report: By Treatment Type (On-Demand, Cure, and Prophylaxis), Therapy Type, Distribution Channel, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Hemophilia A treatment refers to the medical interventions used to manage and treat hemophilia A. In this genetic disorder, the blood lacks sufficient clotting factor VIII, leading to difficulty in blood clotting and an increased risk of excessive bleeding. The primary treatment for Hemophilia A involves replacing the missing clotting factor through factor replacement therapy, which can be either recombinant or plasma-derived.

The hemophilia A treatment market is driven by advancements in therapeutic options, including gene therapy, extended half-life factor VIII products, and non-factor replacement therapies like emicizumab. Growing awareness about hemophilia and its management, along with increasing healthcare investments, is enhancing access to treatments, particularly in emerging markets.

Opportunities exist in developing innovative therapies that address the genetic root causes and improve patient compliance through less invasive treatment options such as subcutaneous injections. A notable trend is the development of extended half-life factor VIII products, offering reduced dosing frequency. Additionally, significant investments in innovative therapies, including non-factor replacement products and gene-editing technologies, are shaping the market landscape.

Hemophilia A Treatment Market Report Highlights

Based on treatment type, prophylaxis holds the largest share in the hemophilia A treatment market due to its ability to prevent bleeding episodes and improve patient quality of life. It is increasingly favored for long-term management, particularly among younger patients.

By therapy type, the factor replacement therapy segment dominates the market, with recombinant and plasma-derived factor VIII products being widely used for on-demand treatment and prophylaxis. Gene therapy & monoclonal antibodies is the fastest-growing segment, offering potential long-term solutions.

Hospital pharmacies are the dominant distribution channel due to their critical role in acute care and emergency treatment. Specialty pharmacies are registering the fastest growth, particularly for advanced therapies like gene therapy and monoclonal antibodies.

North America holds the largest market share, driven by a well-established healthcare infrastructure and high adoption of innovative therapies. Asia Pacific is the fastest-growing region, fueled by expanding healthcare access, rising patient awareness, and increasing investments in emerging economies.

Polaris Market Research has segmented the hemophilia A treatment market report on the basis of treatment type, therapy type, distribution channnel, and region:

By Treatment Type Outlook (Revenue - USD Billion, 2020-2034)

  • On-Demand
  • Cure
  • Prophylaxis

By Therapy Type Outlook (Revenue - USD Billion, 2020-2034)

  • Factor Replacement Therapy
  • Desmopressin & Fibrin Sealants
  • Gene Therapy & Monoclonal Antibodies

By Distribution Channel Outlook (Revenue - USD Billion, 2020-2034)

  • Hospital Pharmacies
  • Specialty Pharmacies

By Regional Outlook (Revenue - USD Billion, 2020-2034)

  • North America
  • US
  • Canada
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Netherlands
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • Malaysia
  • South Korea
  • Indonesia
  • Australia
  • Vietnam
  • Rest of Asia Pacific
  • Middle East & Africa
  • Saudi Arabia
  • UAE
  • Israel
  • South Africa
  • Rest of Middle East & Africa
  • Latin America
  • Mexico
  • Brazil
  • Argentina
  • Rest of Latin America

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Source
    • 3.2.1. Primary Source
    • 3.2.2. Secondary Source

4. Global Hemophilia A Treatment Market Insights

  • 4.1. Hemophilia A Treatment Market - Market Snapshot
  • 4.2. Hemophilia A Treatment Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Advancements in Gene Therapy
      • 4.2.1.2. Adoption of Extended Half-Life Products
      • 4.2.1.3. Rise of Non-Factor Replacement Therapies
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High Cost of Treatments
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Hemophilia A Treatment Market Application Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Hemophilia A Treatment Market, by Treatment Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • 5.3. On-Demand
    • 5.3.1. Global Hemophilia A Treatment Market, by On-Demand, by Region, 2020-2034 (USD Billion)
  • 5.4. Cure
    • 5.4.1. Global Hemophilia A Treatment Market, by Cure, by Region, 2020-2034 (USD Billion)
  • 5.5. Prophylaxis
    • 5.5.1. Global Hemophilia A Treatment Market, by Prophylaxis, by Region, 2020-2034 (USD Billion)

6. Global Hemophilia A Treatment Market, by Therapy Type

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • 6.3. Factor Replacement Therapy
    • 6.3.1. Global Hemophilia A Treatment Market, by Factor Replacement Therapy, by Region, 2020-2034 (USD Billion)
  • 6.4. Desmopressin & Fibrin Sealants
    • 6.4.1. Global Hemophilia A Treatment Market, by Desmopressin & Fibrin Sealants, by Region, 2020-2034 (USD Billion)
  • 6.5. Gene Therapy & Monoclonal Antibodies
    • 6.5.1. Global Hemophilia A Treatment Market, by Gene Therapy & Monoclonal Antibodies, by Region, 2020-2034 (USD Billion)

7. Global Hemophilia A Treatment Market, by Distribution Channel

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 7.3. Hospital Pharmacies
    • 7.3.1. Global Hemophilia A Treatment Market, by Hospital Pharmacies, by Region, 2020-2034 (USD Billion)
  • 7.4. Specialty Pharmacies
    • 7.4.1. Global Hemophilia A Treatment Market, by Specialty Pharmacies, by Region, 2020-2034 (USD Billion)

8. Global Hemophilia A Treatment Market, by Geography

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Hemophilia A Treatment Market Assessment, b y Geography, 2020-2034 (USD Billion)
  • 8.3. Hemophilia A Treatment Market - North America
    • 8.3.1. North America: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
    • 8.3.2. North America: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
    • 8.3.3. North America: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.3.4. Hemophilia A Treatment Market - US
      • 8.3.4.1. US: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.3.4.2. US : Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.3.4.3. US : Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.3.5. Hemophilia A Treatment Market - Canada
      • 8.3.5.1. Canada: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.3.5.2. Canada: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.3.5.3. Canada: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 8.4. Hemophilia A Treatment Market - Europe
    • 8.4.1. Europe: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
    • 8.4.2. Europe: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
    • 8.4.3. Europe: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.4. Hemophilia A Treatment Market - UK
      • 8.4.4.1. UK: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.4.4.2. UK: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.4.4.3. UK: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.5. Hemophilia A Treatment Market - France
      • 8.4.5.1. France: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.4.5.2. France: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.4.5.3. France: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.6. Hemophilia A Treatment Market - Germany
      • 8.4.6.1. Germany: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.4.6.2. Germany: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.4.6.3. Germany: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.7. Hemophilia A Treatment Market - Italy
      • 8.4.7.1. Italy: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.4.7.2. Italy: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.4.7.3. Italy: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.8. Hemophilia A Treatment Market - Spain
      • 8.4.8.1. Spain: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.4.8.2. Spain: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.4.8.3. Spain: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.9. Hemophilia A Treatment Market - Netherlands
      • 8.4.9.1. Netherlands: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.4.9.2. Netherlands: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.4.9.3. Netherlands: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.10. Hemophilia A Treatment Market - Russia
      • 8.4.10.1. Russia: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.4.10.2. Russia: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.4.10.3. Russia: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.11. Hemophilia A Treatment Market - Rest of Europe
      • 8.4.11.1. Rest of Europe: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.4.11.2. Rest of Europe: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.4.11.3. Rest of Europe: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 8.5. Hemophilia A Treatment Market - Asia Pacific
    • 8.5.1. Asia Pacific: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
    • 8.5.2. Asia Pacific: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
    • 8.5.3. Asia Pacific: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.4. Hemophilia A Treatment Market - China
      • 8.5.4.1. China: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.5.4.2. China: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.5.4.3. China: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.5. Hemophilia A Treatment Market - India
      • 8.5.5.1. India: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.5.5.2. India: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.5.5.3. India: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.6. Hemophilia A Treatment Market - Malaysia
      • 8.5.6.1. Malaysia: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.5.6.2. Malaysia: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.5.6.3. Malaysia: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.7. Hemophilia A Treatment Market - Japan
      • 8.5.7.1. Japan: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.5.7.2. Japan: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.5.7.3. Japan: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.8. Hemophilia A Treatment Market - Indonesia
      • 8.5.8.1. Indonesia: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.5.8.2. Indonesia: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.5.8.3. Indonesia: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.9. Hemophilia A Treatment Market - South Korea
      • 8.5.9.1. South Korea: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.5.9.2. South Korea: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.5.9.3. South Korea: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.10. Hemophilia A Treatment Market - Australia
      • 8.5.10.1. Australia: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.5.10.2. Australia: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.5.10.3. Australia: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.11. Hemophilia A Treatment Market - Rest of Asia Pacific
      • 8.5.11.1. Rest of Asia Pacific: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.5.11.2. Rest of Asia Pacific: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.5.11.3. Rest of Asia Pacific: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 8.6. Hemophilia A Treatment Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
    • 8.6.2. Middle East & Africa: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
    • 8.6.3. Middle East & Africa: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.6.4. Hemophilia A Treatment Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.6.4.2. Saudi Arabia: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.6.4.3. Saudi Arabia: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.6.5. Hemophilia A Treatment Market - UAE
      • 8.6.5.1. UAE: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.6.5.2. UAE: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.6.5.3. UAE: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.6.6. Hemophilia A Treatment Market - Israel
      • 8.6.6.1. Israel: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.6.6.2. Israel: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.6.6.3. Israel: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.6.7. Hemophilia A Treatment Market - South Africa
      • 8.6.7.1. South Africa: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.6.7.2. South Africa: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.6.7.3. South Africa: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.6.8. Hemophilia A Treatment Market - Rest of Middle East & Africa
      • 8.6.8.1. Rest of Middle East & Africa: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.6.8.2. Rest of Middle East & Africa: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.6.8.3. Rest of Middle East & Africa: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 8.7. Hemophilia A Treatment Market - Latin America
    • 8.7.1. Latin America: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
    • 8.7.2. Latin America: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
    • 8.7.3. Latin America: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.7.4. Hemophilia A Treatment Market - Mexico
      • 8.7.4.1. Mexico: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.7.4.2. Mexico: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.7.4.3. Mexico: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.7.5. Hemophilia A Treatment Market - Brazil
      • 8.7.5.1. Brazil: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.7.5.2. Brazil: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.7.5.3. Brazil: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.7.6. Hemophilia A Treatment Market - Argentina
      • 8.7.6.1. Argentina: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.7.6.2. Argentina: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.7.6.3. Argentina: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.7.7. Hemophilia A Treatment Market - Rest of Latin America
      • 8.7.7.1. Rest of Latin America: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.7.7.2. Rest of Latin America: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.7.7.3. Rest of Latin America: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. CSL Behring
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Pfizer Inc.
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Novo Nordisk A/S
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Takeda Pharmaceutical Company Limited
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Bayer AG
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Sanofi (through its acquisition of Bioverativ)
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. F. Hoffmann-La Roche Ltd.
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Octapharma AG
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Grifols S.A.
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. BioMarin Pharmaceutical Inc.
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development
  • 10.11. Spark Therapeutics (a subsidiary of Roche)
    • 10.11.1. Company Overview
    • 10.11.2. Financial Performance
    • 10.11.3. Product Benchmarking
    • 10.11.4. Recent Development
  • 10.12. Aptevo Therapeutics
    • 10.12.1. Company Overview
    • 10.12.2. Financial Performance
    • 10.12.3. Product Benchmarking
    • 10.12.4. Recent Development
  • 10.13. Kedrion Biopharma
    • 10.13.1. Company Overview
    • 10.13.2. Financial Performance
    • 10.13.3. Product Benchmarking
    • 10.13.4. Recent Development
  • 10.14. Sangamo Therapeutics
    • 10.14.1. Company Overview
    • 10.14.2. Financial Performance
    • 10.14.3. Product Benchmarking
    • 10.14.4. Recent Development
  • 10.15. uniQure N.V.
    • 10.15.1. Company Overview
    • 10.15.2. Financial Performance
    • 10.15.3. Product Benchmarking
    • 10.15.4. Recent Development

List of Tables:

  • Table 1 Global Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 2 Global Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 3 Global Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 4 North America: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 5 North America: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 6 North America: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 7 US: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 8 US : Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 9 US : Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 10 Canada: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 11 Canada: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 12 Canada: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 13 Europe: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 14 Europe: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 15 Europe: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 16 UK: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 17 UK: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 18 UK: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 19 France: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 20 France: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 21 France: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 22 Germany: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 23 Germany: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 24 Germany: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 25 Italy: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 26 Italy: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 27 Italy: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 28 Spain: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 29 Spain: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 30 Spain: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 31 Netherlands: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 32 Netherlands: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 33 Netherlands: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 34 Russia: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 35 Russia: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 36 Russia: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 37 Rest of Europe: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 38 Rest of Europe: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 39 Rest of Europe: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 40 Asia Pacific: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 41 Asia Pacific: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 42 Asia Pacific: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 43 China: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 44 China: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 45 China: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 46 India: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 47 India: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 48 India: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 49 Malaysia: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 50 Malaysia: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 51 Malaysia: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 52 Japan: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 53 Japan: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 54 Japan: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 55 Indonesia: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 56 Indonesia: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 57 Indonesia: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 58 South Korea: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 59 South Korea: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 60 South Korea: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 61 Australia: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 62 Australia: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 63 Australia: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 64 Rest of Asia Pacific: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 65 Rest of Asia Pacific: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 66 Rest of Asia Pacific: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 67 Middle East & Africa: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 68 Middle East & Africa: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 69 Middle East & Africa: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 70 Saudi Arabia: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 71 Saudi Arabia: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 72 Saudi Arabia: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 73 UAE: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 74 UAE: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 75 UAE: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 76 Israel: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 77 Israel: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 78 Israel: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 79 South Africa: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 80 South Africa: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 81 South Africa: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 82 Rest of Middle East & Africa: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 83 Rest of Middle East & Africa: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 84 Rest of Middle East & Africa: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 85 Latin America: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 86 Latin America: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 87 Latin America: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 88 Mexico: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 89 Mexico: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 90 Mexico: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 91 Brazil: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 92 Brazil: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 93 Brazil: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 94 Argentina: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 95 Argentina: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 96 Argentina: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 97 Rest of Latin America: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 98 Rest of Latin America: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 99 Rest of Latin America: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

List of Figures:

  • Figure 1. Global Hemophilia A Treatment Market, 2020-2034 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Price
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Treatment Type
  • Figure 7. Global Hemophilia A Treatment Market, by Treatment Type, 2024 & 2034 (USD Billion)
  • Figure 8. Market by Therapy Type
  • Figure 9. Global Hemophilia A Treatment Market, by Therapy Type, 2024 & 2034 (USD Billion)
  • Figure 10. Market by Distribution Channel
  • Figure 11. Global Hemophilia A Treatment Market, by Distribution Channel, 2024 & 2034 (USD Billion)